IMPT-514

N/A

Report date: 2026/01/29 20:00:06
First In Class

Base Information

Drug NameIMPT-514
Drug Alias NameIMPT-514
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19Anti-CD20
TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20
Therapy Area/IndicationsLupus Erythematosus, SystemicAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisLupus Nephritis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaDiscontinued
Originator CompaniesImmPACT Bio USA Inc
China Registration ClassN/A

Develop Information

Active CompaniesImmPACT Bio USA Inc
Inactive CompaniesThe Affiliated Nanjing Drum Tower Hospital Of Nanjing University Medical SchoolLyell Immunopharma Inc
Active IndicationsMultiple Sclerosis
Inactive IndicationsLupus Erythematosus, SystemicAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisLupus Nephritis +[4] 

Other Information

ATC CodeN/A
Related LinksN/A